Surmodics Inc. (SRDX) has agreed to be acquired by GTCR, a private equity firm, for $43.00 per share in cash, equating to a total equity value of roughly $627 million.
The company has developed Drug-coated balloons or DCB devices for use in vascular interventions for the treatment of peripheral artery disease.
For its second quarter ended March 31, 2024, Surmodics reported total revenue of $32.0 million compared to $27.2 million in the second quarter of fiscal 2023.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.